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Aims: Although diabetic retinopathy has long been considered a microvascular complication, retinal 
neurodegeneration and inflammation may precede its clinical manifestations. Despite all research efforts, 
the primary treatment options remain laser photocoagulation and anti-vascular endothelial growth factor 
(VEGF) intravitreal injections, both aggressive and targeting the late stages of the disease. Medical 
treatments addressing the early phases of diabetic retinopathy are therefore needed. We aimed at 
verifying if thiamine and fenofibrate protect the cells of the inner blood-retinal barrier from the metabolic 
stress induced by diabetic-like conditions. 
Methods: Human microvascular endothelial cells (HMECs), retinal pericytes (HRPs) and Müller cells (MIO-
M1) were cultured in intermittent high glucose (intHG) and/or hypoxia, with addition of fenofibrate or 
thiamine. Modulation of adhesion molecules and angiogenic factors was addressed. 
Results: Integrins β1/αVβ3 and ICAM1 were upregulated in HMECs/HRPs cultured in diabetic-like 
conditions, as well as metalloproteases MMP2/9 in HRP, with a reduction of their inhibitor TIMP1; MMP2 
increased also in HMEC, and TIMP1 decreased in MIO-M1. VEGF and HIF-1α were strongly increased in 
HMEC in intHG+hypoxia, and VEGF also in HRP. Ang-1/2 augmented in HMEC/MIO-M1, and MCP-1 in 
HRP/MIO-M1 in intHG+hypoxia. Thiamine was able to normalize all such abnormal modulations, while 
fenofibrate had effects in few cases only. 
Conclusions: We suggest that endothelial cells and pericytes are more affected than Müller cells by 
diabetic-like conditions. Fenofibrate shows a controversial behavior, potentially positive on Müller cells and 
pericytes, but possibly detrimental to endothelium, while thiamine confirms once more to be an effective 
agent in reducing diabetes-induced retinal damage.  
 
 






Diabetic retinopathy (DR) has long been considered a microvascular complication. However, retinal 
neurodegeneration and inflammation have recently come into focus as events preceding the clinical 
manifestations of this complication [1]. Despite the efforts of the last decades, the primary options for DR 
treatment remain laser photocoagulation and anti-vascular endothelial growth factor (VEGF) intravitreal 
injections, both invasive and targeting the late stages of the disease. Therefore, medical treatments 
addressing the early phases of DR are strongly needed. 
Among all actors involved in the pathogenesis of early DR, cells belonging to the inner blood-retinal barrier 
(iBRB) are primarily involved. While endothelial cells (ECs) are the first target for potentially damaging 
circulating metabolites, pericytes play a central role in iBRB maintenance [2]. Müller cells, on the other 
hand, constitute the link between the vascular and neural sides of the retina. In DR, they contribute to 
neuronal dysfunction, chronic inflammation and production of pro-angiogenic factors leading to 
neovascularization [3].  
Thiamine (T), an essential cofactor for key-enzymes involved into intracellular glucose metabolism, acts as 
an anti-oxidant against hyperglycemic-induced damage. Diabetic patients are subjected to renal loss of 
thiamine via proximal tubules, with reduction in thiamine availability and transketolase activity [4]. 
Thiamine supplementation reduces progression of DR and nephropathy in diabetic animals [5, 6]. A major 
role for thiamine transporter-2 (THTR2) in thiamine transport inside retinal cells and its involvement in high 
glucose-induced damage and impaired thiamine availability has been recently postulated [7]. 
Fenofibric acid (FA), the active form of fenofibrate, is commonly used to treat dyslipidemia. Its possible role 
in reducing the progression of DR was postulated by two major clinical trials, the FIELD study [8] and the 
ACCORD-Eye study [9], but the mechanisms of action are still poorly understood [10]. FA seems to act as an 
anti-inflammatory agent [11, 12], but also as an anti-angiogenic element, by inhibiting neovascularization 
[13].  
The aim of this study was to verify if thiamine and fenofibrate protect the iBRB from the metabolic stress 
induced by diabetic-like conditions, addressing their potential involvement in the modulation of adhesion 




A human retinal pericyte (HRP) line was stabilized in our laboratory [14]. Human microvascular endothelial 
cells (HMECs) were purchased from ATCC (Cat#CRL-3243, RRID:CVCL_0307), and the human Müller cell line 
Moorfields/Institute of Ophthalmology-Müller 1 (MIO-M1) (RRID:CVCL_0433) obtained from the UCLB 
licensing portal XIP (London, UK) [15]. HRP and MIO-M1 cells were cultured in DMEM+10%FCS; HMEC in 
EBM-2 growth medium (Lonza) for expansion and DMEM+10%FCS for experiments.  
Cells were cultured for 8 days in physiological conditions (NG, 5.6 mmol/l D-glucose), or intHG (48hr high 
glucose, 28 mmol/l /48hr NG, twice), to better mimic the diabetic microenvironment, since we had 
previously demonstrated that human pericytes are more affected by intermittent high glucose conditions 
[16]. 50 µmol/l thiamine (T) and 100 µmol/l fenofibric acid (FA) (concentrations chosen on the basis of 
previous reports [7, 10]) were added during the whole 8-day incubation. Hypoxic conditions (hypo) were 
obtained by keeping cultures in a 5%CO2 / 94%N2 /1%O2 gas mixture for the last 48 hrs.  




Expression of integrins β1 (CD29), αvβ3 (CD51/61) and Intercellular Adhesion Molecule-1 (ICAM-1/CD54) 
was measured through a CytoFLEX flow cytometer (Beckman Coulter), with CytExpert software. Antibodies  
(dilution 1:20) were: anti-CD51/CD61-FITC (ThermoFisher Scientific Cat#11-0519-42, RRID:AB_1907402), 
anti-CD29-FITC (ThermoFisher Cat#11-0299-41, RRID:AB_2043830), anti-ICAM-1-PE (Thermo Fisher Cat#12-
0549-42, RRID:AB_10598517). 
Western blot analysis 
Expression of metalloproteases 2/9 (MMP2/MMP9), their tissue inhibitor TIMP1, VEGF and hypoxia-
inducible factor 1 (HIF-1) was evaluated by Western blot. To extract total proteins, cells were lysed using 
M-PER Mammalian Protein extraction reagent (ThermoFisher) with 10 µl/ml protease inhibitor cocktail kit 
(ThermoFisher), extracts cleared by centrifugation at 20,000 g for 15 min at 4°C and protein content 
measured through Bradford reaction. 30 µg protein were loaded on pre-cast gels (4–20% Mini-PROTEAN® 
TGX™ Precast Gel, Bio-Rad), separated by electrophoresis and transferred to nitrocellulose membranes. 
Immunoblotting was performed using specific antibodies (dilution 1:500): anti-MMP2 (ThermoFisher, 
Cat#MA5-17122, RRID:AB_2538593), anti-MMP9 (ThermoFisher, Cat#MA5-15888, RRID:AB_11157869), 
anti-TIMP1 (ThermoFisher, Cat#MA5-23756, RRID:AB_2609828), anti-VEGF (SantaCruz Biotechnology, 
Cat#sc-7269, RRID:AB_628430), anti-HIF-1 (SantaCruz, Cat#sc-13515, RRID:AB_627723). Bands were 
visualized using the enhanced chemiluminescence (ECL) WB protocol (Merck-Millipore), and the relative 
signal strength quantified by densitometric analysis (1D Image Analysis System, Kodak) and normalized 
against β-actin (Sigma-Aldrich, Cat#A5316, RRID:AB_476743).  
ELISA 
Release of Angiopoietin 1 and 2 (Ang-1/Ang-2), platelet-derived growth factor B (PDGF-B) and Monocyte 
Chemoattractant Protein 1 (MCP-1) was measured by ELISA. Kits used were: Angiopoietin 1 Human ELISA 
Kit (ThermoFisher, Cat# EHANGPT1), Angiopoietin-2 Human ELISA Kit (ThermoFisher, Cat#KHC1641), PDGF-
BB Human ELISA Kit (ThermoFisher, Cat#EHCSRP2), Human MCP-1 Platinum ELISA Kit (Invitrogen, 
Cat#BMS281CE). 
Vessel-like formation assay 
15,000 HRPs and 15,000 HMECs were seeded together onto Matrigel-coated 24-well plates and cultured in 
DMEM. 30,000 HRPs or 30,000 HMECs seeded alone served as controls. After 24 h, phase-contrast photos 
at 100x of five random fields/well were captured. The total length of the structures in each field was 
measured using the MicroImage analysis system (Casti Imaging, Venice, Italy), and the mean of 5 fields/well 
calculated. Each measure was performed in duplicate wells and expressed as ratio of control. 
Statistical analysis 
Statistical comparison was performed by ANOVA with Bonferroni post-hoc correction. Results were 
expressed as mean ± SD of 5 independent experiments, as previously established through a power analysis, 
and normalized against cells cultured in physiological conditions (NG). The SPSS software version 24.0 (IBM) 




Since pericyte detachment/migration is a key-event in DR pathogenesis, we examined the expression of 
adhesion molecules, affected by diabetes: integrin β1, integrin αVβ3 and ICAM-1. All of them (Fig. 1) 
showed an increase in HMEC cultured in intHG+hypo (p<0.05 vs NG ctrl), with integrin β1 also increased in 
NG+hypo (p<0.05 vs NG ctrl) (Fig. 1 a, d, g). Thiamine normalized these altered expressions, while FA had 
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positive effects on ICAM-1 only (Fig. 1g). In HRP, integrin β1 expression was augmented in intHG and 
intHG+hypo (p<0.05 vs NG ctrl) (Fig. 1b), and ICAM-1 in intHG+hypo (p<0.05 vs NG ctrl) (Fig. 1h); all of them 
were normalized by thiamine supplementation, but not FA. Expression of integrins β1, αVβ3 and ICAM-1 
was unchanged in Müller cells, independently of treatment (Fig. 1c,f,i). 
Matrix metalloproteases 
We evaluated the expression of MMP2 and MMP9, and their inhibitor TIMP1, because of their strict 
involvement in the mechanisms of the iBRB disruption [17, 18] (Fig. 2). Both MMP2 and MMP9 were 
increased, and TIMP1 reduced, in HRP cultured in intHG/intHG+ hypo (p<0.05 vs NG ctrl). IntHG and 
hypoxia worked synergistically in increasing MMP2 (p<0.05 for intHG+hypo vs intHG) (Fig. 2b,e,h). Thiamine 
was able to correct altered MMP2/9 expression and, partly, TIMP1 (Fig. 2b,e), while FA normalized MMP9 
expression, when added to intHG+hypo (Fig. 2e). MMP2 expression increased also in HMEC cultured in 
intHG+hypo and was corrected by T, but not FA (Fig.2a). As regards Müller cells, no differences were found 
in MMP2/MMP9 expression in diabetic-like conditions, but T addition decreased their expression in 
comparison with basal conditions (Fig. 2c,f), while TIMP1 expression decreased in hypoxic treatment (Fig. 
2i). 
Angiogenic/inflammatory factors 
DR is characterized by vessel sprouting, abnormal angiogenesis and inflammation. We studied a panel of 
factors, involved in these processes (Fig. 3-4). The most affected were VEGF and HIF-1α (Fig. 3), 
dramatically increased (2.5/3-fold, p<0.05 vs NG ctrl) in HMEC cultured in intHG+hypo and corrected by 
both T and FA (Fig. 3a,d). VEGF was enhanced also in HRP cultured in hypoxic conditions, regardless of 
glucose concentrations, and normalized by thiamine (Fig. 3b). Unexpectedly, VEGF decreased in Müller cells 
cultured in diabetic-like conditions (Fig. 3c). 
IntHG, with/without hypoxia, augmented Ang-1 and Ang-2 release by HMEC and Müller cells, but not 
pericytes (Fig. 4). Thiamine normalized Ang-2 production in HMEC (Fig. 4d), and FA reduced Ang-1 release 
in MIO-M1, when added to intHG+hypo (Fig. 4c). Surprisingly, FA enhanced both Ang-1 and Ang-2 
production by HMEC (Fig. 4a,d). 
PDGF-B, responsible for vessel stabilization, was unchanged in all cell types in diabetic-like conditions (Fig. 
4g,h,i), but FA increased its production in HMEC in all conditions and in MIO-M1 in intHG+hypo (Fig. 4g,i). 
MCP-1 release, a marker of inflammation, was enhanced in HRP and Müller cells in intHG+hypo and 
normalized by FA (Fig. 4j,k). MCP-1 release by HMEC was undetectable with this method. 
The scheme in Fig. 5 shows a summary of the possible interactions among all these different molecules 
involved in diabetes-induced damage.  
Tube formation assay 
To evaluate the capability of our system to produce neo-vascularization in response to diabetic-like stimuli, 
we co-cultured HMECs and HRPs in Matrigel. Vessel-like formation after 24h was increased by 15%, when 
cells were pre-cultured in intHG (p<0.05 vs NG ctrl) (Fig. 6), and thiamine reverted this effect. However, 
vessel formation was strongly decreased in cells submitted to hypoxic treatment, probably because HMEC 





Finding non-invasive pharmacological treatments to prevent or arrest the development of DR is a primary 
goal. We studied the effects of two molecules that have been addressed as potential treatments, thiamine 
and fenofibrate, on cell models mimicking the iBRB, in the diabetic retinal microenvironment.  
The iBRB is involved in the early phases of DR. Endothelial cells are directly exposed to the hyperglycemic 
insult from the blood flow, while pericytes play a key-role in the maintenance of the iBRB: their loss and 
migration are probably the primum movens of the disease, followed by capillary closure, hypoxia and 
generation of angiogenic molecules. Loss of pericyte control on endothelial proliferation leads to new 
vessel sprouting and, eventually, angiogenesis [2]. Müller cells, spread across the whole retina and linking 
its vascular and neural sides [3], are responsible for the uptake of neurotransmitters and nutrients and, in 
diabetes, can contribute to neuronal dysfunction, inflammation and angiogenesis by releasing cytokines, 
chemokines and growth factors [3].  
The in vitro model of the iBRB we re-created using species-specific cells only is meant as close as possible to 
the human retinal microenvironment in diabetic-like conditions: pericytes and Müller cells are of retinal 
origin, while HMECs, though derma-derived, are largely used as models for the study of various diseases, 
including DR [19]. We chose intermittent high glucose conditions for our experimental setting, because 
HRP, ECs and Müller cells are more sensitive to intermittent than stable high glucose [16, 20, 21] and, in 
real life, diabetic patients are continuously subjected to glucose fluctuations. It has also been postulated 
that glycemic excursions may cause retinal neurodegeneration in type 1 diabetes [22]. 
Our results show increased expression of integrin vβ3, integrin subunit β1 and ICAM-1 in ECs exposed to 
fluctuating high glucose and hypoxia. β1 and ICAM-1 were increased also in pericytes, but not in Müller 
cells. Thiamine supplementation reduced this overexpression. Cell surface integrins play important roles in 
the integrity of extracellular matrix (ECM), but also bind and internalize several other molecules [23]. 
Integrins vβ3, vβ1 and 2β1 are involved in angiogenesis, the latter through their subunit β1, by 
promoting cell migration, proliferation and survival of angiogenic ECs [23]. ICAM-1 is mainly expressed by 
EC and leukocytes, following cytokine stimulation. Leukocytes are involved in the pathogenesis of many 
retinal diseases, among which DR [24], and their adhesion is regulated by ICAM-1 and MCP-1 [23, 24]. 
ICAM-1 is also involved in angiogenesis, as VEGF can enhance its expression [24]. 
Increased MMP2 and MMP9 expression, and the concomitant reduction of TIMP1, as found in our cell 
models, are consistent with our previous findings showing dysregulation of the MMPs/TIMP1 system in 
HRPs due to high glucose damage [17], as well as increased MMP2 in the same cells exposed to 
extracellular vesicles released in diabetic-like conditions [18]. Our present results demonstrate that 
thiamine supplementation corrects this damage. MMPs are primarily involved in ECM degradation, but 
they are also able to cleave other non-ECM proteins, including growth factors and cytokines [25]. MMP2 
and MMP9 enhance angiogenesis, modulating several mechanisms, such as VEGF [25], and hyperglycemia 
induces MMP upregulation via oxidative stress and AGE formation [25]. MMP2 and MMP9 are expressed 
also by Müller cells [26]: cytokines induce upregulation of MMP9 [26] and there is evidence of increased 
MMPs in high glucose conditions [21]. Increased levels of MMP2 and MMP9 were found in the retina and 
vitreous of DR patients [27]. However, we could not detect any modulation of MMP2 and 9 in Müller cells, 
apart from a decrease following thiamine supplementation. 
The hypoxic microenvironment characteristic of DR induces the nuclear translocation of HIF-1α, which 
binds to inducible target genes, increasing expression of angiogenic proteins, such as VEGF [28]. In a 
previous paper, we demonstrated that HIF-1α expression is increased in circulating extracellular vesicles 
from DR subjects [29]. VEGF is secreted ubiquitously inside the retina and its expression is also modulated 
by high glucose [28]. It induces both increased iBRB permeability and angiogenesis, two major events of DR, 
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and its expression is augmented in the vitreous and aqueous humor of DR patients [30]. Consistently with 
previous findings, our results show a major increase of HIF-1 in ECs cultivated in hyperglycemic and 
hypoxic conditions, with a consequent rise of VEGF. VEGF was also upregulated in pericytes by hypoxia, 
while Müller cells were not affected. Addition of thiamine was again able to normalize enhanced VEGF and 
HIF-1 release. 
Ang-1 and Ang-2 are strictly involved in the pathological mechanisms at the basis of DR, since they partly 
regulate pericyte recruitment and endothelial cell survival [31]. In our experiments, we found upregulation 
of both of them in diabetic-like conditions in ECs and Müller cells, but not pericytes. Thiamine was able to 
normalize Ang-2 in ECs and Ang-1 in Müller cells, while FA increased both Ang-1 and Ang-2 release by ECs. 
Ang-1 has a dual role in angiogenesis: as an angiogenic factor, it plays a key-role in pericyte recruitment and 
vessel stabilization [32], but it has also been shown to inhibit tumor growth [31] and abnormal angiogenesis 
during DR [31]. Ang-2 has been long considered as an antagonist of Ang-1, as it binds the same receptor 
(Tie2), with a role in vascular disruption. However, it has also agonist functions, depending on the context 
[33]. Ang-2 expression is increased in vascular cells by hyperglycemia [31], inflammatory mediators [33], 
hypoxia and VEGF [34], and its role in pericyte dropout during DR has been demonstrated [31]. Müller cells 
showed increased Ang-2 expression under hyperglycemic conditions in vitro [31]. Interestingly, Ang-2 can 
exert angiogenic functions also independently of Tie2, by binding directly to integrins, especially the β1 
subunit [35].  
PDGF-B/PDGF-receptor β signaling is crucial for the proliferation, migration and recruitment of pericytes to 
the microvasculature [36]. Hyperglycemia reduces PDGF-B/PDGFR-β signaling in animal models of DR, 
leading to pericyte apoptosis and pro-inflammatory responses, and inducing release of MCP-1 from 
endothelium [37]. MCP-1 acts as a potent inflammatory factor inside the retina, released mostly by Müller 
cells, its levels correlating with VEGF production, changes in BRB permeability, leukocyte recruitment, and 
induction of superoxide from monocytes/macrophages [25]. Its expression is increased in patients with 
ocular diseases, such as DR [30]. Consistently, we found a decrease in PDGF-B in ECs cultured in fluctuating 
glucose concentrations, corrected by thiamine supplementation, and increased MCP-1 release by pericytes 
and Müller cells, normalized by FA addition. MCP-1 was undetectable in ECs. 
The relationship among all the molecules investigated in this study and involved in diabetes-induced 
damage is summarized in Fig. 5.  
Thiamine is beneficial in preventing damage caused by hyperglycemia in vitro and in animal models [7, 38, 
39]. This effect is obtained mainly through its anti-oxidant properties, as it reduces increased ROS 
production, by acting on the four metabolic branches of the unifying mechanism proposed to mediate 
glucose-induced injury [5, 40, 41]. Thiamine deficiency leads to a pseudo-hypoxic state, with accumulation 
of VEGF and HIF-1 [42]. Thiamine acts also indirectly on ECM impairment in hyperglycemic conditions, 
which causes pericyte loss [43]. In diabetic animals, thiamine reduced diabetic nephropathy and DR [5, 6]. 
Diabetic patients show renal loss of thiamine, causing kidney damage [4]. Recently, two SNPs in SLC19A3 
gene encoding for THTR2 were associated with absent/low DR and nephropathy in long-term type-1 
diabetes [44] and primary involvement of THTR2 in thiamine transport inside retinal cells, with a role in 
hyperglycemic-induced damage and impaired thiamine availability was hypothesized [7]. Our results show a 
generalized beneficial effects of thiamine supplementation on all the metabolic pathways addressed, 
possibly achieved by switching off the activating signal cascade initiated by free radical accumulation. 
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. Two clinical trials, the 
FIELD study [8] and the ACCORD-Eye study [9], showed that it reduces the risk of progression of DR. 
However, its mechanisms of action in DR remain unclear, though almost certainly independent of its lipid-
lowering effects [10]. Increased blood vessel permeability and retinal vascular leakage in diabetic animal 
models were ameliorated by PPARα overexpression and administration of oral FA [11], suggesting a role as 
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an anti-inflammatory agent [12]. Moreover, FA prevents the disruption of the outer BRB [45] and could also 
have anti-angiogenic effects, reducing expression of VEGF receptor-2 in ECs, thus inhibiting 
neovascularization [13]. Other studies show a negative modulation of VEGF and decreased loss of ECs and 
pericytes in the presence of FA [46]. However, in other districts, FA was shown to have opposite effects, 
restoring impaired VEGF production and migration in EC [47]. 
In our study, FA supplementation reduced integrin β1, MMP9, Ang-1 and MCP-1 expression in pericytes in 
diabetic-like conditions, as well as Ang-1 and MCP-1 in Müller cells. However, surprisingly, it exhibited 
controversial effects on ECs, slowing down their proliferation and increasing Ang-1/Ang-2 release, while 
conversely lowering VEGF/HIF-1 expression. This reflects also on the tube formation assay, where cells 
exposed to FA form very few new tubes in comparison with physiological control, with a rather suffering 
aspect. Since we have chosen the same FA concentration found beneficial in previous reports on retinal 
cells [10, 13, 45], these effects could rather be due to our experimental setting, that implies 8-day 
exposure, instead of the 48h treatment used by most of the other works, and should be taken into account 
when extrapolating data from cell cultures exposed for very short periods to different drugs. 
Conclusions 
Taken together, our results show that microvascular cells of the iBRB are more affected than Müller cells by 
the hyperglycemic and hypoxic insult characteristic of the diabetic retinal microenvironment. Müller cells 
are known to be very resistant elements, as they produce several self-protective factors and begin to die off 
later than pericytes and ECs in the natural history of DR [3]. FA shows a controversial behavior, potentially 
positive on Müller cells and HRP, but possibly damaging on endothelium, while thiamine confirms once 
more to be effective in reducing diabetes-induced retinal damage. 
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Fig. 1 Expression of the adhesion molecules integrin β1 (CD29) (a, b, c), integrin αVβ3 (CD51/61) (d, e, f) and ICAM-1 
(CD54) (g, h, i) in HMECs (a, d, g), HRPs (b, e, h) and Müller cells (c, f, i), as detected by FACS analysis. White bars: NG, 
light grey bars: NG+hypo, dark grey bars: intHG, black bars: intHG+hypo. CTR: control, T: thiamine, FA: fenofibrate. 




Fig. 2 Expression of metalloproteases MMP2 (a, b, c), MMP9 (d, e, f) and their inhibitor TIMP1 (g, h, i) in HMECs (a, d, 
g), HRPs (b, e, h) and Müller cells (c, f, i), as detected by WB in cell lysates. White bars: NG, light grey bars: NG+hypo, 
dark grey bars: intHG, black bars: intHG+hypo. CTR: control, T: thiamine, FA: fenofibrate. N=5, * p<0.05 vs NG CTR, $ 






Fig. 3 VEGF (a, b, c) and HIF-1 (d, e, f) expression in HMECs (a, d), HRPs (b, e) and Müller cells (c, f), as detected by 
WB in cell lysates. White bars: NG, light grey bars: NG+hypo, dark grey bars: intHG, black bars: intHG+hypo. CTR: 
control, T: thiamine, FA: fenofibrate. N=5, * p<0.05 vs NG CTR, # p<0.05 vs NG+hypo CTR, $ p<0.05 vs intHG CTR § 




Fig. 4 Ang-1 (a, b, c) , Ang-2 (d, e, f), PDGF-BB (g, h, i) and MCP-1 (j, k) release by HMECs (a, d, g), HRPs (b, e, h, j) and 
Müller cells (c, f, i, k), as detected by ELISA in cell culture supernatants. MCP-1 release by HMEC was undetectable 
with this method. White bars: NG, light grey bars: NG+hypo, dark grey bars: intHG, black bars: intHG+hypo. CTR: 
control, T: thiamine, FA: fenofibrate. N=5, * p<0.05 vs NG CTR, # p<0.05 vs NG+hypo CTR, $ p<0.05 vs intHG CTR § 






Fig. 5 Interactions among the different molecules involved in diabetes-induced damage, as described in the literature 
and examined in this work. Hyperglycemia and hypoxia directly, or indirectly through increased ROS/HIF-1 
production, enhance expression of cell surface molecules (integrin vβ3, integrin subunit β1, ICAM-1, MMP2/9), 
involved in pericyte loss and angiogenesis. The hypoxic microenvironment induces the nuclear translocation of HIF-1α, 
which binds to inducible target genes, modulating the expression of VEGF, integrins, MCP-1 and Ang-1. VEGF, the 
main actor of retinal angiogenesis, has direct effects on BRB permeability, pericyte loss and inflammation, but also 
stimulates Ang-2 and ICAM-1 expression. Ang-1/2 regulate pericyte recruitment and EC survival and their increase in 
hyperglycemic and hypoxic conditions correlates with enhanced angiogenesis and inflammation. PDGF-B/PDGF-
receptor β signaling is crucial for the recruitment of pericytes and vessel stabilization: hyperglycemia reduces PDGF-
B/PDGFR-β signaling leading to pericyte apoptosis, and inducing release of MCP-1, a potent inflammatory factor 
whose levels correlate with VEGF production and changes in BRB permeability. Thiamine deficiency leads to a pseudo-






Fig. 6 Tube formation by HMECs and HRPs co-cultured in Matrigel. a-l) representative images of one field per each 
case. a, b, c, d: CTRL; e, f, g, h: thiamine supplementation; i, j, k, l: FA supplementation. a, e, i: NG; b, f, j: NG+hypo; c, 
g, k: intHG, d, h, l: intHG+ hypo. m) mean of 5 different experiments. White bars: NG, light grey bars: NG+hypo, dark 
grey bars: intHG, black bars: intHG+hypo. CTR: control, T: thiamine, FA: fenofibrate. * p<0.05 vs NG CTR, # p<0.05 vs 
NG+hypo CTR, $ p<0.05 vs intHG CTR § p<0.05 vs intHG+hypo CTR 
 
 
 
 
